Skip to content

Seaweed, the Food Matrix, and Iodine Bioavailability

Seaweed, the Food Matrix, and Iodine Bioavailability

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04867291
Acronym
IoBio
Enrollment
12
Registered
2021-04-30
Start date
2021-04-30
Completion date
2021-11-30
Last updated
2021-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iodine Bioavailability

Brief summary

This study explores the influence of the food matrix of seaweed-containing food products on iodine bioavailability. The investigation will ascertain whether iodine bioavailability (as a percentage of the dose ingested that is excreted in urine) is comparable between seaweed sheets, seaweed powder (in capsules), pizza fortified with powdered seaweed, and potassium iodide supplements.

Detailed description

Iodine deficiency can have serious consequences, especially during pregnancy and lactation where the fetus is entirely dependent on its mother for the provision of iodine. There is no current iodine fortification programme in the United Kingdom, and the main sources of iodine are from dietary sources, such as dairy products and seafood. However, seaweed is also a rich source of iodine; the inclusion of iodine (via powdered seaweed) in commonly consumed foods is of potential benefit as a strategy, as it removes the need for consumers to alter their dietary behaviours, which are often culturally standardized. Seaweed intake (via supplements) can increase the iodine status of women with habitually low-iodine diets. However, reduced bioavailability of iodine from the seaweed matrix has also been displayed, which could impact iodine intake should individuals choose to use seaweed as a dietary source of iodine. This study tests the influence of the food matrix of seaweed-containing products on iodine bioavailability. This will be evaluated over the course of 27 days, in a randomized crossover trial design with 4 arms. Each arm will be separated by 7 washout days, and participants will follow a low iodine diet (avoiding all seafood, seaweed products, eggs, dairy, fortified plant milk and goitrogens (cabbage, soy etc.) for the 2 days preceding and the 1 day following each feed. 1. Food arm: portion equivalent to 200µg of iodine, half a pizza (Eat Balanced pizza) (consumed with \ 450mL of water) 2. Seaweed sheet arm: portion equivalent to 200µg of iodine, \ 10g of seaweed sheets (consumed alongside 2 slices of white bread and \ 450mL of water) 3. Seaweed powder arm: portion equivalent to 200µg of iodine, 1 capsule (consumed alongside 2 slices of white bread and \ 450mL of water). 4. Potassium iodide supplement arm: portion equivalent to 200µg of iodine with \ 450mL of water (Piping Rock Potassium Iodide Supplement, consumed alongside 2 slices of white bread) Iodine excretion will be monitored in urine collected during the 12 hours preceding and 36 hours following the meal. Urine will be collected in 8 timed fractions (0-1h, 1-2h, 2-3h, 3-5h, 5-8h, 8-12h, 12-24h, 24-36h) and participants will be provided with containers and instructions on how to collect their urine. A single fecal sample will also be collected before the first feed, and within 24 hours of all feeds. Participants will also keep a detailed food diary on all study days to enable iodine ingestion monitoring.

Interventions

DIETARY_SUPPLEMENTPizza

Portion equivalent to 200 µg of iodine (half a pizza), consumed with \ 450mL of water.

DIETARY_SUPPLEMENTSeaweed Sheets

Portion equivalent to 200 µg of iodine (\ 10g), consumed with two slices of white bread and \ 450mL of water.

DIETARY_SUPPLEMENTSeaweed Powder

Portion equivalent to 200 µg of iodine (1 capsule), consumed with two slices of white bread and \ 450mL of water.

DIETARY_SUPPLEMENTPotassium iodide

Portion equivalent to 200 µg of iodine (1.3 tablets), consumed with two slices of white bread and \ 450mL of water.

Sponsors

University of Glasgow
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 48 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy * Premenopausal women * 18-48 years old * Signed informed consent

Exclusion criteria

* Pregnancy and lactation * Past and present thyroid conditions/dysfunction * Allergy to gluten, wheat, or dairy * Iodine supplement consumption * Currently taking medication (other than contraceptive) * Diseases of the gastrointestinal tract * Current smoker * Current vegan (pizza contains dairy cheese) * Having a habitual diet very low in iodine (\<1 portion of dairy per day, or \<1 portion of fish per week) * Having a habitual diet very high in iodine (\>4 portions of dairy per day, or \>4 portions of fish per week)

Design outcomes

Primary

MeasureTime frameDescription
Urinary Iodine Excretion (micrograms/L)36 hoursThe percentage of iodine ingested from the test foods that is excreted in the 36 hours following test food ingestion will be measured in urine collected fractions: 1-2, 2-3, 3-5, 5-7, 7-12, 12-24, 24-36 hours

Secondary

MeasureTime frameDescription
Fecal Iodine Excretion (micrograms/g feces)24 hoursThe percentage of iodine ingested from the test foods that is excreted in a single fecal sample passed in the 24 hours following test food ingestion

Other

MeasureTime frameDescription
Gut Bacterial DiversityPrior to commencement of trialAssessed via single fecal sample
Seaweed Fermentation CapacityPrior to commencement of trialAssessment of the capacity of participants' gut microflora to ferment seaweed polysaccharides and release iodine from the food matrix. Assessed via single fecal sample used in an in vitro fermentation model.

Contacts

Primary ContactMartha L Redway, BSc
m.redway.1@research.gla.ac.uk07510924724
Backup ContactEmilie Combet, PhD
emilie.combetaspray@glasgow.ac.uk0141 201 8527

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026